Clinical trials: sponsored by Celgene
Healthy Volunteers
A Study to Assess Safety, Tolerability, and Pharmacokinetics of CC-92480 Formulations in Healthy Adult Participants
This is a Phase 1 study that will be conducted in 2 parts. Participants may participate in 1 part only. Part 1 will be a randomized, double-blind, placebo-controlled, single ascending dose study to evaluate the safety…
- Trial name
- NCT04839809
- Testing
- CC-92480
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Celgene
B-cell Chronic Lymphocytic Leukemia
A Study to Evaluate the Efficacy and Safety of Lenalidomide as Maintenance Therapy for Patients With B-Cell Chronic Lymphocytic Leukemia (CLL) Following Second Line Therapy
The purpose of this study is to determine if lenalidomide (Revlimid®) is safe and effective as a maintenance therapy at improving further the quality of the response you achieved with your last therapy and at prolonging the…
- Trial name
- NCT00774345
- Testing
- Lenalidomide
- Where
- 241 sites in United States, Australia and 23 more
- Volunteers
- 317 people
- Sponsor
- Celgene
Healthy Volunteers
A Study to Evaluate the Effect of a Dual CYP2C19 and CYP3A4 Inhibitor, Fluconazole, on the Pharmacokinetics of Fedratinib in Healthy Adult Subjects
This study is designed to test the effect of fluconazole (a dual CYP2C19 and CYP3A4 inhibitor) on the Pharmacokinetics (PK) of fedratinib.
- Trial name
- NCT04702464
- Testing
- Fedratinib, Fluconazole
- Where
- United States
- Volunteers
- 29 people, healthy volunteers welcome
- Sponsor
- Celgene
Healthy Volunteers
A Study to Evaluate the Metabolism and Excretion of [14C]-CC-92480 in Healthy Male Participants
This is a single-center, open-label study to be conducted in healthy adult male participants. This study is designed to characterize the biotransformation and excretion of [14C]-CC-92480 and to evaluate the safety and…
- Trial name
- NCT04560738
- Testing
- [14C]-CC-92480
- Where
- United States
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Celgene
Healthy Volunteers
A Study to Evaluate Effects of CC-99677 on the Pharmacokinetics of an Oral Contraceptive in Healthy Female Participants
The purpose of this study is to evaluate the effect of CC-99677 coadministration on the pharmacokinetics (PK) of an oral contraceptive (OC).
- Trial name
- NCT04718636
- Testing
- Oral Contraceptive (Ortho Tri-Cyclen or its generic equivalent), CC-99677
- Where
- 3 sites in United States
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Celgene
Lymphoma, B-Cell
Study to Evaluate Tolerability of Iberdomide (CC-220) in Combination With Polatuzumab Vedotin Plus Rituximab or Tafasitamab or Rituximab Plus Chemotherapy in B-cell Lymphoma
This is a Phase 1b/2 randomized study of Iberdomide (CC-220) added to 3 different combination regimens (polatuzumab vedotin plus rituximab (Cohort A), tafasitamab (Cohort B), rituximab plus gemcitabine and platinum-based…
- Trial name
- NCT04882163
- Testing
- CC-220, Polatuzumab vedotin, Rituximab
- Where
- 27 sites in United States, Austria and 6 more
- Sponsor
- Celgene
Glioblastoma Multiforme, Squamous Cell Carcinoma of Head and Neck
Study to Assess Safety and Tolerability of Oral CC-115 for Patients With Advanced Solid Tumors, and Hematologic Malignancies.
The main purpose of this first human study with CC-115 is to assess the safety and action of a new class of experimental drug (dual DNA-PK and TOR kinase inhibitors) in patients with advanced tumors unresponsive to standard…
- Conditions
- Glioblastoma Multiforme, Squamous Cell Carcinoma of Head and Neck, Prostate Cancer, Ewing's Osteosarcoma
- Trial name
- NCT01353625
- Testing
- CC-115
- Where
- 17 sites in United States, France and 2 more
- Volunteers
- 118 people
- Sponsor
- Celgene
Healthy Volunteers
Study to Evaluate the Pharmacokinetic Comparability of CC-93538 From Two Different Drug Concentrations in Healthy Adult Subjects
This is an open-label, randomized, parallel design study to evaluate the PK comparability, safety, tolerability and immunogenicity of a single SC dose of 360 mg CC 93538 using two different drug concentrations, 180 mg/mL and 150…
- Trial name
- NCT04373187
- Testing
- CC-93538
- Where
- United States
- Volunteers
- 52 people, healthy volunteers welcome
- Sponsor
- Celgene
Leukemia, Lymphocytic, Chronic, B-Cell
A Phase 1/2, Open-label, Dose Finding Study to Evaluate CC-122 in Combination With Ibrutinib and Obinutuzumab in Subjects With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Safety, pharmacokinetics, and preliminary efficacy of CC-122 alone and in combination with ibrutinib and obinuzutumab. CC-122 has multiple activities, including immune modulation of several immune cell subsets and…
- Trial name
- ENHANCE (NCT02406742)
- Testing
- CC-122, Ibrutinib, Obinutuzumab
- Where
- 24 sites in United States, Austria and 3 more
- Volunteers
- 47 people
- Sponsor
- Celgene
Healthy Volunteers
A Study to Evaluate the Relative Bioavailability of a Pediatric Granule Formulation of Ozanimod in Healthy Adult Subjects
This is a Phase 1, open-label, randomized, parallel-group, single-dose study. Approximately 56 participants will be enrolled and randomized into 1 of the 2 treatment groups, with 28 participants in each treatment group as…
- Trial name
- NCT04528290
- Testing
- Ozanimod
- Where
- United States
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Celgene
Multiple Myeloma
Post-authorisation Study of Biological Relapse in Patients With Multiple Myeloma
Post-authorisation prospective follow-up study to assess the clinical impact on time to progression (TTP) from the start of anti- multiple myeloma treatment at the onset of asymptomatic relapse/biological progression versus start…
- Trial name
- EPA-MMBR (NCT02394210)
- Where
- 44 sites in Spain
- Volunteers
- 415 people
- Sponsor
- Celgene
Ulcerative Colitis
Safety and Efficacy Trial of RPC1063 for Moderate to Severe Ulcerative Colitis
The purpose of this study is to determine whether RPC1063 is effective in the treatment of Ulcerative Colitis (UC).
- Trial name
- NCT02435992
- Testing
- RPC1063
- Where
- 372 sites in United States, Argentina and 28 more
- Volunteers
- 1,012 people
- Sponsor
- Celgene
Healthy Volunteers, Psoriasis
A Safety Study of CC-92252 in Healthy Adult Subjects and Adult Subjects With Psoriasis
This is a phase 1, randomized, single-center, 3-part, study to assess the safety, tolerability, PK, and PD, of single and multiple doses of CC-92252 in healthy adult subjects and multiple doses of CC-92252 in adult subjects with…
- Trial name
- NCT03971825
- Testing
- CC-92252
- Where
- Germany
- Volunteers
- 131 people, healthy volunteers welcome
- Sponsor
- Celgene
Multiple Myeloma
Efficacy and Safety of Pomalidomide and Dexamethasone in RRMM Patients With Renal Insufficiency
The primary purpose of the study is to determine the safety and efficacy and to generate PK and biomarker data for the combination of Pomalidomide and low-dose Dexamethasone in patients with relapsed or refractory multiple…
- Trial name
- NCT02045017
- Testing
- Pomalidomide and Dexamethasone
- Where
- 22 sites in Austria, France and 6 more
- Volunteers
- 81 people
- Sponsor
- Celgene
Healthy Volunteer
A Study to Evaluate Potential Cytochrome P450 and Transporter Protein Interactions With CC-99677
It is a phase 1, open-label, single-center, three-part study to assess the safety, tolerability, and pharmacokinetics of multiple doses of CC-99677 administered alone or in combination with either methotrexate and sulfasalazine…
- Trial name
- NCT04268394
- Testing
- CC-99677, Methotrexate, Sulfasalazine
- Where
- United Kingdom
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Celgene
Multiple Myeloma
A Study to Assess Renal Function Response to Treatment in Patients With Relapsed Multiple Myeloma and Creatinine Clearance
A prospective, multicentre, post-authorisation observational study. The objective of this study is assess the response of renal function in clinical practice to anti-multiple myeloma therapy in patients with relapsed MM and CrCl…
- Trial name
- MIR50 (NCT02849444)
- Testing
- Anti-myeloma treatment at physician discretion
- Where
- 40 sites in Spain
- Volunteers
- 326 people
- Sponsor
- Celgene
Hematologic Neoplasms
A Phase 1, Dose Finding Study of CC-90002 in Subjects With Advanced Solid and Hematologic Cancers
CC-90002-ST -001 is an open-label, Phase 1, dose escalation clinical study in subjects with advanced, refractory solid and hematologic cancers.
- Trial name
- NCT02367196
- Testing
- CC-90002, Rituximab
- Where
- 13 sites in United States, Spain
- Volunteers
- 60 people
- Sponsor
- Celgene
Multiple Myeloma
A Study to Evaluate the My Hematology Oncology Patient Experience (MyHOPE™) For Multiple Myeloma (MM) Digital Care Network in Patients With MM
NDS-MM-004 is a multi-center, randomized, pilot trial to evaluate the MyHOPE for multiple myeloma (MM) Platform in patients with MM.
- Trial name
- MyHOPE™ (NCT04730505)
- Testing
- MyHOPE™ for Multiple Myeloma, MyHope HCP Portal
- Where
- 34 sites in United States
- Volunteers
- 2 people
- Sponsor
- Celgene
Healthy Volunteer
Metabolism and Excretion of [14C]CC-90001 in Healthy Male Subjects
This is a clinical pharmacology study to characterize the biotransformation and excretion of [14C]CC-90001 and to evaluate the safety and tolerability of [14C]CC-90001 following a single oral dose of [14C]CC-90001 in healthy male…
- Trial name
- NCT04655898
- Testing
- [14C]CC-90001
- Where
- United States
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Celgene
Leukemia, Myeloid, Acute
Survival in Patients Older Than 60 Years With Newly Diagnosed AML in Spain
Prospective, multicenter, observational, national study (EPA-SP) that aims to describe the survival and the quality of life, the clinical management strategies and the prognostic factors for survival related to the patient, in a…
- Trial name
- NCT03435341
- Where
- 40 sites in Spain
- Volunteers
- 151 people
- Sponsor
- Celgene